Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AteBrO: Atezolizumab in ER+ Breast Cancer
NCT04630210Phase 1Withdrawn
- Sponsor
- UZ Leuven
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in breast cancer (4 arms), sponsored by UZ Leuven. Primary endpoints: Ki67 decrease and Stromal Tumor Infiltrating Lymphocytes increase. Planned start Feb 2021; status: withdrawn.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04630210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630210.